This meeting was intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing information was available at the meeting and is available here.
Adverse events should be reported:Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com.

Head Start Leading Education in Headache Management Leonardo Hotel Hinckley Island Sunday 9 & Monday 10 June 2024

.

Head Start's Annual Meeting 2024

The sixth Head Start educational meeting focused on the latest advancements in headache and migraine management

We explored pertinent topics to gaining a deeper understanding of headache and migraine management strategies. Our esteemed multidisciplinary faculty shared their expertise, to bring attendees up to speed on the latest research.

Meeting agenda

Day one explored the current treatment landscape and vision for the future, there was a keynote session that delved into predictors of response to anti-CGRP monoclonal antibodies, we explored the crucial role of patient empowerment in advocating for effective treatment, and we had immersive collaborative case studies, showcasing how a multidisciplinary team (MDT) can unite to optimise patient care.

Day two aimed to elevate MDT strategies and introduce groundbreaking innovations through a lively panel discussion on enhancing patient care through service redesign, national experts unveiling cutting-edge treatments, and clinical case masterclasses on headaches and hormones and real-world treatment experiences of treatment holidays.

Several of the sessions were recorded and added to our on demand materials

Access On-Demand Recordings

 

Head Start meetings have been rated highly by previous delegates

100% would attend Head Start again*

81% rated the meeting as very successful in hitting their educational objectives*

Meeting was rated 4.9/5 in overall meeting satisfaction*

Chairing Head Start

Dr Mona Ghadiri-Sani, Consultant Neurologist, The Walton Centre NHS Foundation Trust

Meeting Co-Chair

Dr Mona Ghadiri-Sani, Consultant Neurologist, The Walton Centre NHS Foundation Trust

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde

Meeting Co-Chair

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde

As co-chairs, Dr Mona Ghadiri-Sani and Dr Krishna Dani, were delighted to welcome delegates to Head Start 2024

"The Head Start agenda has been developed to explore a range of pivotal subjects, from the behavioural and psychological impact of headache to navigating the ever-evolving treatment landscapes. Engaging talks will cover complex clinical cases and foster multidisciplinary team (MDT) collaboration, promoting holistic approaches to patient care."

.

Steering Committee

Dr Mona Ghadiri-Sani, Consultant Neurologist, The Walton Centre NHS Foundation Trust

Steering Committee Member

Dr Mona Ghadiri-Sani, Consultant Neurologist, The Walton Centre NHS Foundation Trust

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde

Steering Committee Member

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde

Professor Peter Goadsby, Professor of Neurology, King's College, London

Steering Committee Member

Professor Peter Goadsby, Professor of Neurology, King's College, London

Mrs Claire Fisher, Nurse Specialist for Headache, University Hospitals Sussex NHS Foundation Trust

Steering Committee Member

Mrs Claire Fisher, Nurse Specialist for Headache, University Hospitals Sussex NHS Foundation Trust

Dr Edward O’Sullivan, Clinical Director, Cork University Hospital​

Steering Committee Member

Dr Edward O’Sullivan, Clinical Director, Cork University Hospital​

Dr Vivek Mehta, Consultant in Pain Medicine, Barts Health NHS Trust

Steering Committee Member

Dr Vivek Mehta, Consultant in Pain Medicine, Barts Health NHS Trust

.

Highlights

Reflections from Head Start 2024

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde, shares his reflections after Head Start's Annual Meeting 2024

Reflections from Head Start 2024

Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde, shares his reflections after Head Start's Annual Meeting 2024

Delegate Feedback

Feedback from attendees of previous Head Start meetings

Delegate feedback

Head Start's Annual Meeting 2022

All sessions were very good. I enjoyed the parrallel sessions. There were lots of take home messages.

Delegate feedback

Head Start's Annual Meeting 2022

It has given me a great learning experience

Delegate feedback

Head Start's Annual Meeting 2022

All the speakers were well informed and presented well

Delegate feedback

Head Start's Annual Meeting 2022

"Thanks Teva for not pushing your own agenda/products and giving speaker freedom to present what they want"

Delegate feedback

Head Start's Virtual Meeting 2021

This meeting is very well organised and easy to book onto.  The speakers were all brilliant and evidently experts in their fields of practice.  Presentations were concise and easy to understand.  Thank you for a very informative meeting.

Delegate feedback

Head Start's Annual Meeting 2019

The Teva team provided an excellent, well organised programme with good IT support, excellent hotel and location. 


Head Start Hub

  • Meeting highlights
  • On demand education
  • Updates on future meetings
Explore the Head Start Hub Head Start Hub
Date of preparation: October 2024
Reference: D: MIG-GB-00229 (V3.0) / T: MIG-GB-00230 (V3.0) / M: MIG-GB-00231 (V3.0)

This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.

Teva Logo.png

Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX  
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.

Privacy Policy | Pharmacovigilance Privacy PolicyTerms and Conditions | AccessibilityReporting Adverse Events